

SCI PHARMTECH, INC. 旭富製藥科技

簡報

ISO 14001

BUREAU VERITAS
Certification



ISO 9001

BUREAU VERITAS
Certification



公司概況Profile



員工數Employee : 245

設立日期：中華民國七十六年九月十八日

Date of establishment: Sep. 18, 1987

資本額Capital：新台幣795佰萬元(NTD 795mn)

營業項目Business：

原料藥API (65.71%)

中間體Intermediate (26.63%)

特用化學品 Custom-made chemicals (7.66%)

製藥產業的上、中、下游 SCI's position

上游
Upstream

基本原料 RM



中間體 Intermediate:
生產原料藥之
中間步驟所產出之產品 Products before API



中游
Midstream

原料藥 API:
製劑中之有效成分 Curative ingredient



下游
Downstream

製劑: 成品藥 Formulation

旭富營業範圍
SCI's businesses

公司概況 Outline

	Jan~Sep.2018	Y2017
歐洲Europe	38.54%	42.07%
美洲America	35.02%	21.29%
亞洲Asia	13.70%	21.37%
國內Taiwan	10.90%	14.21%
其他 others	1.84%	1.06%
合計Total	100.00%	100.00%

營運概況-IS

Unit: K NTD

	2018.H1	2017Y
營收Sales	956,083	1,301,050
營業成本COGS	(589,725)	(906,694)
毛利Gross Profit	366,358	394,356
毛利率 GP Ratio	38.3%	30.3%
營業費用Operating Expenses	(128,655)	(161,307)
營業利益Operating Income	237,703	233,049
營業外損益Non-Operating In/Ex	19,197	1,725
稅前淨利 Net Profit before Tax	256,900	234,774
所得稅Income Tax	(46,809)	(43,798)
本期淨利Net Profit after Tax	210,091	190,976

產品組合-Products

Y2015	%		Y2016	%		Y2017	%
HOCLQ	21.52		HOCLQ	34.94		S-MMAA / Dulo	13.14
VA Series	18.21		PGA	12.73		VA Series	12.48
PGA	17.14		VA Series	13.55		HOCLQ	12.47
LPF.Na	7.48		Pent-2 / PEB.Na	6.70		LPF.Na	9.41
5-HMT / 5-wing	4.61		S-MMAA / Dulo	5.32		PGA	9.22
Pent-2 / PEB.Na	4.47		5-HMT / 5-wing	5.21		Pent-2 / PEB.Na	8.69
S20/38	4.01		LPF.Na	4.01		5-HMT / 5-wing	6.26
S-MMAA / Dulo	3.81						
Total	81.25		Total	82.46		Total	71.67

產品組合-Products

Product	%	Jan~Sep.2018 (NT\$)
HOCLQ Sulfate	27.54	406,402,509
VA series	15.77	232,735,656
S-MMAA / Dulo	13.19	194,675,105
PGA	9.16	135,126,960
Pent-2 / PEB.Na	6.48	95,606,113
Olivetol / PMDOL	4.72	69,648,284
BZA	2.37	34,950,184


重點產品介紹 Product Profile

- Hydroxychloroquine Sulfate
- (S)-MMAA / Duloxetine HCl
- VA / DiVANa / NaVA
- Menthadienol / Olivetol / Ethyl Olivetolate
- Brinzolamide
- Benzhydrylamine / 3-Azetidinol
- Ritalinic acid / Methylphenidate
- d-Ritalinic acid / Dexmethylphenidate

Hydroxychloroquine sulfate

- 適應症 Application:


類風濕性關節炎(rheumatoid arthritis)、瘧疾(malaria)、慢性多形性日光疹、慢性圓板狀紅斑症(discoid and systemic lupus erythematosus)



S-MMAA/Duloxetine HCl

- 適應症 Application:


重鬱症(major depressive disorder)、廣泛性焦慮症
(generalized anxiety disorder)、糖尿病週邊神經痛
(diabetic neuropathy)、纖維肌痛 (Fibromyalgia)、
慢性腰痛(日本地區) lower back pain (only in Japan)



VA Series:

Valproic Acid, Divalproex Sodium, Sodium Valproate

- 適應症 Application :
癲癇(seizure)、躁鬱症(bipolar disorder)、
偏頭痛(migraine headaches)



Menthadienol, Olivetol, Ethyl Olivetolate (1)

1. Dronabinol 之關鍵中間體

Key intermediate of Dronabinol

- 適應症 Applications :

- ① 化療引起的噁心、嘔吐

Nausea and vomiting due to chemotherapy

- ② 愛滋病引起之厭食症 anorexia due to AIDS

Menthadienol, Olivetol, Ethyl Olivetolate (2)

2. Cannabidiol (CBD, 大麻二酚)之關鍵中間體 Key intermediate of CBD
- CBD之應用廣泛：癲癇、巴金森氏症、阿茲海默症、躁鬱、焦慮、止痛、抗發炎等。
 - 與THC(四氫大麻酚)不同，CBD沒有其精神副作用及成癮性。
 - FDA 於 6/25 批准 Epidiolex (GW之大麻二酚新藥)，適用於兒童的兩種罕見癲癇以及多發性硬化症，開啟了大麻衍生藥物療法的新紀元。
 - CBD has a wide range of medical benefits, helping with issues like epilepsy, Parkinson's and Alzheimer's disease, bipolar disorder, anxiety, pain, inflammation, etc.
 - Unlike THC, CBD has no intoxicating effects.
 - FDA approved Epidiolex (new drug of GW) on June 25, for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome in patients aged 2 years and older, and Multiple Sclerosis. This has become a milestone of Cannabinoids derivatives.

Brinzolamide

- 適應症 Application：青光眼 (glaucoma)
- 單方：Brinzolamide
- 複方：Brinzolamide+Timolol,
Brinzolamide+Brimonidine tartrate
- 製劑需求量 (FDF consumption): ~2MT, US\$ 6.3億
(9/30/2016~9/30/2017)。

Benzhydrylamine / 3-Azetidinol

- 適應症 Application：降血壓 (hypertension)、新抗生素 (new antibiotics)、新阿茲海默症中間體 (intermediate used for new Alzheimer treatment)

Ritalinic acid / Methylphenidate (MEPH)

d-Ritalinic acid / Dexmethylphenidate (dex-MEPH)

- 適應症 Application :
注意力不足 (attention deficit hyperactivity disorder (ADHD)
、過動症 (narcolepsy)
- MEPH 製劑需求量 (FDF consumption):
38MT, US\$ 32.4億 (9/30/2016~9/30/2017) 。
- Dex-MEPH製劑需求量 (FDF consumption):
2.4MT, US\$ 7億 (9/30/2016~9/30/2017) 。

新市場 (New Market) :

與印度、中國、俄羅斯及新興國家之合作

Partner with India, China, Russia and Emerging countries

新藥方向 (New drugs):

- 1) 大麻二酚 (CBD)
- 2) 中樞神經用藥 (CNS)
- 3) 失智症 (dementia)
- 4) 癌症用藥 (oncology)
- 5) 管制藥 (controlled substance)

No.	API	DMF (USA)	CEP (EDQM)	MF (Japan)	DMF (Canada)	CGMP certified (TFDA)
1	Valproic Acid	2003	2004	2008	2008	2003
2	Probucol	2004		2017	2015	2015
3	Divalproex Sodium	2005			2010	2005
4	Propafenone Hydrochloride	2010	2012	2012	2012	2010
5	Duloxetine Hydrochloride	2011	2014	2017	2016	2012
6	Allopurinol	2011	2003			2004
7	Clindamycin Palmitate HCl	2011				
8	Articaine Hydrochloride	2014	2016			2013
9	Hydroxychloroquine Sulfate	2014			2014	2014
10	Brinzolamide	2015		2017		2015
11	Sodium Valproate		2006	2017		2004
12	Pentobarbital Sodium		2011			2009
13	Methylphenidate HCl		2014			2011
14	Bisoprolol Fumarate					2006
15	Thiopental acid					2012
16	Loxoprofen Sodium Hydrate			2011		2012
17	Atomoxetine HCl					2016

簡報完畢



敬請指教